In addition to this, a variety of polyclonal antibodies against LHCGR and monoclonal antibodies against LH were tested during assay development

In addition to this, a variety of polyclonal antibodies against LHCGR and monoclonal antibodies against LH were tested during assay development. Results == Pre-treatment sLHCGR identified many women at risk of ovarian hyperstimulation. Low levels of sLHCGR were associated with pregnancy in both high and low responders but sLHCGR did not significantly affect the treatment outcome of intermediate responders. Low BQ-788 responders who failed to become pregnant had high levels of circulating sLHCGR bound to LH (LH-sLHCGR). == Conclusions == Pre-treatment measurement of sLHCGR could be used to tailor individual fertility treatment programs and improve outcomes by avoiding ovarian hyperstimulation and poor embryo implantation. Keywords:soluble LHCGR, LH-LHCGR, AMH, FSH, OHSS, IVF, Pregnancy == Background == Given that about three-quarters of human embryos created by assisted reproductive technology (ART) such as IVF and ICSI fail to produce live births following uterine transfer [1], there has been increasing interest in identifying pre-treatment factors that may indicate the likelihood of success with fertility treatments. The follicle stimulating hormone [FSH] and luteinizing hormone [LH], play central roles in the maturation of the ovarian follicles and ovulation. Following ovulation, the remaining cells of the follicle are luteinized by LH and secrete progesterone plus oestradiol which are necessary for implantation of the embryo [2]. One of the important aspects of the female reproductive cycle is that ovulation is controlled by a pulsatile secretion of LH (LH surge) that is subject to individual variation [3]. In controlled ovarian stimulation (COS), this variability of ovarian activities is temporarily eliminated by GnRH agonists/antagonists, while at the same time the ovarian functions are regulated by exogenously injected FSH and LH/hCG [4-7]. In addition to routine estimation of LH and FSH, the serum concentrations of anti-mullerian hormone (AMH) are often measured prior to COS. While LH or FSH alone or together provide a measure of the ovarian activity, AMH is the reliable marker for functional ovarian reserve [8]. Moreover, high AMH levels (> 45 pmol/L) are indicative of polycystic ovary (PCO) and these patients are BQ-788 usually susceptible to ovarian hyperstimulation syndrome (OHSS) following hormonal induction. The serum AMH concentrations, being independent of the phase of the reproductive cycle, also appear to have some predictive Rabbit polyclonal to HES 1 value with respect to the pregnancy outcome [9,10]. The receptors expressed on the surface of target cells for LH and human chorionic gonadotrophin (hCG) binding and signalling are identical and are therefore described as the LH/hCG receptor or LHCGR [11]. In addition to ovary and testis, various isoforms of LHCGR are expressed almost ubiquitously in primary and secondary reproductive organs (uterus, fallopian tube, placenta and breast) and in a variety of extragonadal tissues including vascular endothelial and smooth muscle cells, brain, lymphocytes, macrophages, skin as well as foetal tissues [12,13]. The physiological significance of the extragonadal expression of LHCGR remains unexplained. BQ-788 The earliest experimental evidence of the cell-free existence of LH receptor was its hCG-affinity purification from porcine follicular fluid [14]. The detection of a Mr80-90K LH-LH receptor complex from Leydig cell culture media [15] and a Mr30-60K LH-receptor binding protein in serum from uremic boys suffering from hypogonadism provided further clues to the extracellular appearance of soluble LH receptor. Notably, both soluble LH receptor and the hCG-receptor complexes have been shown to be released from cells transfected with cloned LH receptor [16-18]. However, the clinical significance of the cell-free soluble LHCGR remained unknown due to the lack of a convenient experimental system for quantitative estimation of the soluble receptor in body fluids. We have recently shown that soluble LH/hCG receptor (sLHCGR) is released from LHCGR-transfected cells, placental explants [19] and into the bloodstream of pregnant women. Here, we describe the development and use of quantitative ELISA assays for the measurement of sLHCGR and hormone-receptor complex (LH-sLHCGR) in the serum of women presenting for IVF treatment. BQ-788 The assays described detect the analytes in follicular fluid, serum and plasma samples from the same patient. Our results demonstrate that women with high pre-treatment serum sLHCGR or LH-sLHCGR are usually low responders, produce reduced number of oocytes ( 5 oocytes) and are less likely to become pregnant. In addition, low to undetectable pre-treatment circulating LHCGR/LH-receptor complex is associated with high ovarian response ( 15 oocytes) and OHSS. The clinical applications of these assays in predicting ovarian response to fertility treatment and improving implantation potential following embryo transfer are discussed. == Methods == == Antibodies == Purified LHR29 monoclonal antibody [19,20] was.